Drug manufacturer Boehringer Ingelheim (BI) announced yesterday that it will stop shipping 340B-purchased drugs to hospitals’ contract pharmacies, effective Aug. 1.
Community health centers, HIV/AIDS clinics, and other federal grantee covered entities are exempt from BI’s new policy. It applies to all BI products except the company’s specialty drugs OFEV, Gilotrif, and Praxbind. BI will let hospitals without an in-house pharmacy designate a single contract pharmacy location to receive and dispense BI products. Hospitals will have to register with drug manufacturer vendor 340B ESP to make their contract pharmacy designation.
Drug manufacturer Boehringer Ingelheim (BI) announced yesterday that it will stop shipping 340B-purchased drugs to hospitals’ contract pharmacies, effective Aug. 1.
Community health centers, HIV/AIDS clinics, and other federal grantee covered entities are exempt from BI’s new policy. It applies to all BI products except the company’s specialty drugs OFEV, Gilotrif, and Praxbind. BI will let hospitals without an in-house pharmacy designate a single contract pharmacy location to receive and dispense BI products. Hospitals will have to register with drug manufacturer vendor 340B ESP to make their contract pharmacy designation.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.